Omid Hamid on Responses to Single Agent Immunotherapies Compared to Combination
Omid Hamid, MD, compares the responses of patients with melanoma on single-agent immunotherapy treatment to those on combination therapy treatments.
Omid Hamid, MD, chief of Translational Research and Immunotherapy at The Angeles Clinic, talks about patient responses with single-agent immunotherapy and combination therapies in melanoma.
Hamid explains that the response rate for single-agent immunotherapy treatment is approximately 40%, and for combination treatments, it is approximately 57%. However, these data do not give much information about the long-term benefits of these therapies. Hopefully, comparisons of the overall survival with combination treatments and with single-agent treatment will be forthcoming.
Cemiplimab as Adjuvant Therapy Improves DFS in High-Risk Cutaneous Squamous Cell Carcinoma
January 20th 2025Adjuvant cemiplimab demonstrated a statistically significant improvement in DFS compared to placebo in post-surgical patients with high-risk CSCC, impacting post-operative care considerations.
Stopping ICIs at 1 or 2 Years May Not Compromise Survival in HNSCC
September 11th 2024This retrospective, population-based study shows strong efficacy across multiple patient subgroups and different lines of therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma.
